Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy-Reference-Cited by-同舟云学术

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

Published:2019-06-12 Issue:496 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Claus Christina¹^ORCID,Ferrara Claudia¹,Xu Wei¹,Sam Johannes¹,Lang Sabine¹,Uhlenbrock Franziska²,Albrecht Rosmarie¹,Herter Sylvia¹,Schlenker Ramona¹,Hüsser Tamara¹,Diggelmann Sarah¹,Challier John¹,Mössner Ekkehard¹,Hosse Ralf J.¹,Hofer Thomas¹,Brünker Peter¹,Joseph Catherine³,Benz Jörg³,Ringler Philippe⁴^ORCID,Stahlberg Henning⁴^ORCID,Lauer Matthias³,Perro Mario¹,Chen Stanford¹,Küttel Christine¹,Bhavani Mohan Preethi L.¹,Nicolini Valeria¹,Birk Martina Carola¹,Ongaro Amandine¹,Prince Christophe¹,Gianotti Reto¹,Dugan Gregory⁵,Whitlow Christopher T.⁵^ORCID,Solingapuram Sai Kiran Kumar⁵,Caudell David L.⁵,Burgos-Rodriguez Armando G.⁶,Cline J. Mark⁵^ORCID,Hettich Michael³,Ceppi Maurizio³,Giusti Anna Maria³,Crameri Flavio³,Driessen Wouter³,Morcos Peter N.⁷,Freimoser-Grundschober Anne¹^ORCID,Levitsky Victor¹^ORCID,Amann Maria¹,Grau-Richards Sandra¹,von Hirschheydt Thomas⁸,Tournaviti Stella⁸,Mølhøj Michael⁸,Fauti Tanja¹,Heinzelmann-Schwarz Viola⁹,Teichgräber Volker¹,Colombetti Sara¹,Bacac Marina¹,Zippelius Alfred²,Klein Christian¹^ORCID,Umaña Pablo¹^ORCID

Affiliation:

1. Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development (pRED), Wagistrasse 10, 8952 Schlieren, Switzerland.

2. University of Basel, Department of Biomedicine, Hebelstrasse 20, 4031 Basel, Switzerland.

3. Roche Innovation Center Basel, pRED, Grenzacherstrasse 124, 4070 Basel, Switzerland.

4. University of Basel, Center for Cellular Imaging and NanoAnalytics (C-CINA), Biozentrum, Klingelbergstrasse 70, 4056 Basel, Switzerland.

5. Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.

6. Caribbean Primate Research Center, PO Box 1053, Sabana Seca, Puerto Rico 00952, USA.

7. Roche Innovation Center New York, pRED, 430 E 29th St, New York, NY 10016, USA;

8. Roche Innovation Center Munich, pRED, Nonnenwald 2, 82377 Penzberg, Germany.

9. University Hospital Basel, Gynecological Oncology, Spitalstrasse 21, 4031 Basel, Switzerland.

Abstract

Tumor-targeted 4-1BB agonists provide costimulation as combination partners for cancer immunotherapies in solid and hematological tumors.

Funder

NIH Clinical Center

Swiss National Science Foundation

NCAT

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference62 articles.

1. Elements of cancer immunity and the cancer–immune set point

2. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

3. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies

4. 4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses

5. 4-1BB signaling beyond T cells

Cited by 162 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effective prognostic risk model with cuproptosis-related genes in laryngeal cancer;Brazilian Journal of Otorhinolaryngology;2024-03

2. New immune cell engagers for cancer immunotherapy;Nature Reviews Immunology;2024-01-25

3. 4-1BB immunotherapy: advances and hurdles;Experimental & Molecular Medicine;2024-01-04

4. Cancer-associated fibroblasts in neoadjuvant setting for solid cancers;Critical Reviews in Oncology/Hematology;2024-01

5. M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation;Cancer Immunology Research;2023-12-13